Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major

Annals of Hematology

Volumn 91, Issue 7, 2012, Pages 1107-1114

  Belhoul, Khawla M ^a   Bakir, Maisam L ^a   Saned, Mohamed Salaheldin ^a   Kadhim, Ahmed M A ^a   Musallam, Khaled M ^b   Taher, Ali T ^b  

^a Al Wasl Hospital   (United Arab Emirates)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Diabetes mellitus; Ferritin; Hypogonadism; Hypoparathyroidism; Hypothyroidism; Iron overload; Thalassemia major

Indexed keywords

DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; ENDOCRINE DISEASE; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HYPERSPLENISM; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SPLENECTOMY; SPLENOMEGALY; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; CROSS-SECTIONAL STUDIES; DEFEROXAMINE; ENDOCRINE SYSTEM DISEASES; FEMALE; FERRITINS; HUMANS; HYPOPARATHYROIDISM; HYPOTHYROIDISM; INCIDENCE; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; YOUNG ADULT;

EID: 84862770600     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1412-7     Document Type: Article

References (48)

1. C Hershko 2010 Pathogenesis and management of iron toxicity in thalassemia Ann N Y Acad Sci 1202 1 9 20712765 10.1111/j.1749-6632.2010.05544.x 1:CAS:528:DC%2BC3cXhtFGms7bM
2. AR Cohen E Glimm JB Porter 2008 Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major Blood 111 583 587 17951527 10.1182/blood-2007-08-109306 1:CAS:528:DC%2BD1cXns1Cgug%3D%3D
3. AT Taher KM Musallam A Inati 2009 Iron overload: consequences, assessment, and monitoring Hemoglobin 33 Suppl 1 S46 S57 20001632 10.3109/03630260903346676 1:CAS:528:DC%2BD1MXhsFGrurnK
4. NF Olivieri DG Nathan JH MacMillan AS Wayne PP Liu A McGee M Martin G Koren AR Cohen 1994 Survival in medically treated patients with homozygous beta-thalassemia N Engl J Med 331 574 578 8047081 10.1056/NEJM199409013310903 1:STN:280:DyaK2czit1ynug%3D%3D
5. C Borgna-Pignatti S Rugolotto P De Stefano A Piga F Di Gregorio MR Gamberini V Sabato C Melevendi MD Cappellini G Verlato 1998 Survival and disease complications in thalassemia major Ann N Y Acad Sci 850 227 231 9668544 10.1111/j.1749-6632.1998.tb10479.x 1:STN:280:DyaK1czjtlWnsw%3D%3D
6. V Gabutti A Piga 1996 Results of long-term iron-chelating therapy Acta Haematol 95 26 36 8604584 10.1159/000203853 1:CAS:528:DyaK28XisFymurY%3D
7. C Borgna-Pignatti S Rugolotto P De Stefano H Zhao MD Cappellini GC Del Vecchio MA Romeo GL Forni MR Gamberini R Ghilardi A Piga A Cnaan 2004 Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine Haematologica 89 1187 1193 15477202
8. B Modell M Khan M Darlison MA Westwood D Ingram DJ Pennell 2008 Improved survival of thalassaemia major in the UK and relation to T2*cardiovascular magnetic resonance J Cardiovasc Magn Reson 10 42 18817553 10.1186/1532-429X-10- 42
9. DM Nathan JB Buse MB Davidson E Ferrannini RR Holman R Sherwin B Zinman 2009 Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 193 203 18945920 10.2337/dc08-9025 1:CAS:528:DC%2BD1MXhs1Gns78%3D
10. HJ Baskin RH Cobin DS Duick H Gharib RB Guttler MM Kaplan RL Segal 2002 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism Endocr Pract 8 457 469 15260011
11. D Shoback 2008 Clinical practice. Hypoparathyroidism N Engl J Med 359 391 403 18650515 10.1056/NEJMcp0803050 1:CAS:528:DC%2BD1cXovFWjsLw%3D
12. I Thuret C Pondarre A Loundou D Steschenko R Girot D Bachir C Rose V Barlogis J Donadieu M de Montalembert I Hagege B Pegourie C Berger M Micheau F Bernaudin T Leblanc L Lutz F Galacteros MC Simeoni C Badens 2010 Complications and treatment of patients with beta-thalassemia in France: results of the National Registry Haematologica 95 724 729 20007138 10.3324/haematol.2009.018051
13. MJ Cunningham EA Macklin EJ Neufeld AR Cohen 2004 Complications of beta-thalassemia major in North America Blood 104 34 39 14988152 10.1182/blood-2003-09-3167 1:CAS:528:DC%2BD2cXlslWgsr0%3D
14. TE Delea J Edelsberg O Sofrygin SK Thomas JF Baladi PD Phatak TD Coates 2007 Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review Transfusion 47 1919 1929 17880620 10.1111/j.1537-2995.2007.01416.x 1:CAS:528: DC%2BD2sXht1elsrnN
15. K Musallam MD Cappellini A Taher 2008 Challenges associated with prolonged survival of patients with thalassemia: transitioning from childhood to adulthood Pediatrics 121 e1426 e1429 18450884 10.1542/peds.2007-1944
16. A Piga S Roggero I Salussolia D Massano M Serra F Longo 2010 Deferiprone Ann N Y Acad Sci 1202 75 78 20712776 10.1111/j.1749-6632.2010.05586.x 1:CAS:528:DC%2BC3cXhtFGms7fM
17. R Galanello A Agus S Campus F Danjou PJ Giardina RW Grady 2010 Combined iron chelation therapy Ann N Y Acad Sci 1202 79 86 20712777 10.1111/j.1749-6632. 2010.05591.x 1:CAS:528:DC%2BC3cXhtFGms7fN
18. GM Brittenham 2011 Iron-chelating therapy for transfusional iron overload N Engl J Med 364 146 156 21226580 10.1056/NEJMct1004810 1:CAS:528: DC%2BC3MXmvFartg%3D%3D
19. K Farmaki I Tzoumari C Pappa 2011 Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications Blood Cells Mol Dis 47 33 40 21531154 10.1016/j.bcmd.2011.03.007 1:CAS:528:DC%2BC3MXmvFCns7o%3D
20. MR Gamberini V De Sanctis G Gilli 2008 Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre Pediatr Endocrinol Rev 6 Suppl 1 158 169 19337172
21. K Farmaki I Tzoumari C Pappa G Chouliaras V Berdoukas 2010 Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major Br J Haematol 148 466 475 19912219 10.1111/j.1365-2141.2009.07970.x
22. CH Wang KH Wu FJ Tsai CT Peng CH Tsai 2006 Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients Hemoglobin 30 257 262 16798651 10.1080/03630260600642609 1:CAS:528:DC%2BD28XkvFKms7s%3D
23. O Platis G Anagnostopoulos K Farmaki M Posantzis E Gotsis G Tolis 2004 Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy Pediatr Endocrinol Rev 2 Suppl 2 279 281 16462711
24. S Jaruratanasirikul R Chareonmuang M Wongcharnchailert V Laosombat P Sangsupavanich K Leetanaporn 2008 Prevalence of impaired glucose metabolism in beta-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy Eur J Pediatr 167 873 876 17899188 10.1007/s00431-007-0602-0 1:CAS:528:DC%2BD1cXnvVyjtrk%3D
25. S Shalitin D Carmi N Weintrob M Phillip H Miskin L Kornreich R Zilber I Yaniv H Tamary 2005 Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients Eur J Haematol 74 93 100 15654898 10.1111/j.1600-0609.2004.00371.x 1:CAS:528:DC%2BD2MXitVGns7Y%3D
26. CE Jensen SM Tuck J Old RW Morris A Yardumian V De Sanctis AV Hoffbrand B Wonke 1997 Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia Eur J Haematol 59 76 81 9293854 10.1111/j.1600-0609.1997. tb00729.x 1:STN:280:DyaK2svjvVSkuw%3D%3D
27. PT Telfer E Prestcott S Holden M Walker AV Hoffbrand B Wonke 2000 Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major Br J Haematol 110 971 977 11054091 10.1046/j.1365-2141.2000.02298.x 1:CAS:528:DC%2BD3cXnslCnurs%3D
28. BA Davis C O'Sullivan PH Jarritt JB Porter 2004 Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major Blood 104 263 269 15001468 10.1182/blood-2003-08-2841 1:CAS:528:DC%2BD2cXlslWgsbg%3D
29. JP Carpenter T He P Kirk M Roughton LJ Anderson SV de Noronha MN Sheppard JB Porter JM Walker JC Wood R Galanello G Forni G Catani G Matta S Fucharoen A Fleming MJ House G Black DN Firmin TG St Pierre DJ Pennell 2011 On T2*magnetic resonance and cardiac iron Circulation 123 1519 1528 21444881 10.1161/CIRCULATIONAHA.110.007641
30. TG St Pierre PR Clark W Chua-anusorn AJ Fleming GP Jeffrey JK Olynyk P Pootrakul E Robins R Lindeman 2005 Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance Blood 105 855 861 15256427 10.1182/blood-2004-01-0177 1:CAS:528:DC%2BD2MXltlGmuw%3D%3D
31. JC Wood C Enriquez N Ghugre JM Tyzka S Carson MD Nelson TD Coates 2005 MRI R2 and R2*mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients Blood 106 1460 1465 15860670 10.1182/blood-2004-10-3982 1:CAS:528:DC%2BD2MXosVejtLc%3D
32. P Kirk T He LJ Anderson M Roughton MA Tanner WW Lam WY Au WC Chu G Chan R Galanello G Matta M Fogel AR Cohen RS Tan K Chen I Ng A Lai S Fucharoen J Laothamata S Chuncharunee S Jongjirasiri DN Firmin GC Smith DJ Pennell 2010 International reproducibility of single breathhold T2*mR for cardiac and liver iron assessment among five thalassemia centers J Magn Reson Imaging 32 315 319 20677256 10.1002/jmri.22245
33. LJ Anderson S Holden B Davis E Prescott CC Charrier NH Bunce DN Firmin B Wonke J Porter JM Walker DJ Pennell 2001 Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload Eur Heart J 22 2171 2179 11913479 10.1053/euhj.2001.2822 1:CAS:528:DC%2BD38XisV2ltw%3D%3D
34. de Assis RA, Ribeiro AA, Kay FU, Rosemberg LA, Nomura CH, Loggetto SR, Araujo AS, Fabron Junior A, de Almeida Verissimo MP, Baldanzi GR, Esposito BP, Baroni RH, Wood JC, Hamerschlak N (2011) Pancreatic iron stores assessed by magnetic resonance imaging (MRI) in beta thalassemic patients. Eur J Radiol
35. G Restaino A Meloni V Positano M Missere G Rossi L Calandriello P Keilberg O Mattioni A Maggio M Lombardi G Sallustio A Pepe 2011 Regional and global pancreatic T*2 MRI for iron overload assessment in a large cohort of healthy subjects: normal values and correlation with age and gender Magn Reson Med 65 764 769 21337408 10.1002/mrm.22640
36. WY Au WW Lam W Chu S Tam WK Wong R Liang SY Ha 2008 A T2*magnetic resonance imaging study of pancreatic iron overload in thalassemia major Haematologica 93 116 119 18166794 10.3324/haematol.11768
37. LJ Noetzli J Papudesi TD Coates JC Wood 2009 Pancreatic iron loading predicts cardiac iron loading in thalassemia major Blood 114 4021 4026 19726718 10.1182/blood-2009-06-225615 1:CAS:528:DC%2BD1MXhsVGku7rO
38. JC Wood L Noetzl A Hyderi M Joukar T Coates S Mittelman 2010 Predicting pituitary iron and endocrine dysfunction Ann N Y Acad Sci 1202 123 128 20712782 10.1111/j.1749-6632.2010.05545.x 1:CAS:528:DC%2BC3cXhtFGms7fK
39. N Skordis M Michaelidou SC Savva Y Ioannou A Rousounides M Kleanthous G Skordos S Christou 2006 The impact of genotype on endocrine complications in thalassaemia major Eur J Haematol 77 150 156 16800840 10.1111/j.1600-0609.2006. 00681.x 1:CAS:528:DC%2BD28XovFWrtrc%3D
40. D Tavazzi L Duca G Graziadei A Comino G Fiorelli MD Cappellini 2001 Membrane-bound iron contributes to oxidative damage of beta-thalassaemia intermedia erythrocytes Br J Haematol 112 48 50 11167782 10.1046/j.1365-2141. 2001.02482.x 1:CAS:528:DC%2BD3MXhtl2iu7k%3D
41. Y Aydinok S Bayraktaroglu D Yildiz H Alper 2011 Myocardial iron loading in patients with thalassemia major in Turkey and the potential role of splenectomy in myocardial siderosis J Pediatr Hematol Oncol 33 374 378 21364469 10.1097/MPH.0b013e31820c34ef 1:CAS:528:DC%2BC3MXnvVarsbc%3D
42. A Eldor EA Rachmilewitz 2002 The hypercoagulable state in thalassemia Blood 99 36 43 11756150 10.1182/blood.V99.1.36 1:CAS:528:DC%2BD38XivF2jsA%3D%3D
43. D Rund E Rachmilewitz 2005 Beta-thalassemia N Engl J Med 353 1135 1146 16162884 10.1056/NEJMra050436 1:CAS:528:DC%2BD2MXhtVWhsbnL
44. MD Cappellini I Motta KM Musallam AT Taher 2010 Redefining thalassemia as a hypercoagulable state Ann N Y Acad Sci 1202 231 236 20712798 10.1111/j.1749-6632.2010.05548.x 1:CAS:528:DC%2BC3cXhtFGmsL7P
45. V Atichartakarn K Likittanasombat S Chuncharunee P Chandanamattha S Worapongpaiboon P Angchaisuksiri K Aryurachai 2003 Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders Int J Hematol 78 139 145 12953808 10.1007/BF02983382
46. SE Crary GR Buchanan 2009 Vascular complications after splenectomy for hematologic disorders Blood 114 2861 2868 19636061 10.1182/blood-2009-04-210112 1:CAS:528:DC%2BD1MXht12qur7L
47. A Phrommintikul A Sukonthasarn R Kanjanavanit W Nawarawong 2006 Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia Heart 92 1467 1472 16621878 10.1136/hrt.2005.079970 1:STN:280:DC%2BD28rkvVWgtQ%3D%3D
48. A Aessopos D Farmakis S Deftereos M Tsironi A Polonifi I Moyssakis E Diamanti-Kandaraki E Papalambros 2005 Cardiovascular effects of splenomegaly and splenectomy in beta-thalassemia Ann Hematol 84 353 357 15711802 10.1007/s00277-004-1002-4